Paritosh Garg/LinkedIn
Apr 12, 2026, 14:15
Paritosh Garg: A fibrotic marrow is not always PMF
Paritosh Garg, Associate Consultant at Fortis Memorial Research Institute, India, shared a post on LinkedIn:
“A fibrotic marrow is not always PMF.
One recent case reminded me of this very clearly.
A young woman presented with severe cytopenias, a leucoerythroblastic smear, and grade 2 marrow fibrosis.
The initial marrow appearance was concerning — but the rest of the story mattered.
There was:
- no splenomegaly
- no atypical megakaryocytes
- no significant dysplasia
- no convincing clonal marker
- autoimmune features supporting an immune-mediated process
Her treatment journey was equally telling:
- relapsed on steroids
- did not respond to MMF / cyclosporine / danazol
- finally responded to rituximab
For me, the takeaway was powerful:
- when fibrosis is seen in the marrow, especially in a young patient with autoimmune clues, autoimmune myelofibrosis must remain on the radar.
In hematology, morphology opens the door.
But diagnosis still belongs to the whole clinical picture.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026
-
Jul 14, 2026, 12:02Louise St. Germain Bannon: Our first ISTH regulatory session at ISTH 2026
-
Jul 14, 2026, 11:21Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026
-
Jul 14, 2026, 10:24Sara Zalghout: The Little Things That Make ISTH 2026 Special
-
Jul 14, 2026, 10:11Joseph R. Shaw: GAUGE Advances FXa Inhibitor Reversal at ISTH 2026
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation